Related Experiment Video

Updated: Jun 27, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments

Dorina Veliceasa1, Frank Thilo Schulze-Hoëpfner, Olga V Volpert

  • 1Urology Department, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA.

PPAR Research
|December 2, 2008
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARgamma) influences cancer cell growth and angiogenesis. Research explores its dual role in cancer therapy, highlighting potential benefits and risks of PPARgamma agonists.

Area of Science:

  • Molecular biology
  • Endocrinology
  • Oncology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor with ligands used in treating metabolic disorders.
  • PPARgamma influences cell survival and proliferation, making it a focus of preclinical cancer research.
  • Recent studies indicate PPARgamma's role in modulating angiogenesis both in vitro and in vivo.

Purpose of the Study:

  • To review current knowledge on PPARgamma's regulatory mechanisms and molecular targets.
  • To discuss the potential of PPARgamma as an anticancer drug target.
  • To explore strategies for maximizing the beneficial effects of PPARgamma agonists in cancer therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on PPARgamma in cancer.
  • Analysis of molecular mechanisms underlying PPARgamma's effects on angiogenesis.
  • Synthesis of current findings on PPARgamma's dual role in tumor promotion and inhibition.

Main Results:

  • PPARgamma agonists show potential in treating angiogenesis-dependent diseases like cancer.
  • Evidence suggests PPARgamma can modulate angiogenesis, impacting tumor growth.
  • Some studies report pro-angiogenic and tumor-promoting effects of PPARgamma, necessitating further investigation.

Conclusions:

  • PPARgamma is a significant target for therapies against angiogenesis-dependent cancers and diabetic vascular complications.
  • The complex role of PPARgamma in cancer requires careful consideration of its agonists' effects.
  • Further research is needed to optimize the therapeutic application of PPARgamma agonists.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.